Researchers from across the globe will be gathering in Geneva, Switzerland, for the 2019 European Lung Cancer Congress.
New findings of various research teams on use of bevacizumab in nonsquamous non–small-cell lung cancer (NSCLC) will be discussed during the meeting. A report on investigation of the immune-modulatory effects of a regimen of paclitaxel, carboplatin, and bevacizumab in patients with advanced NSCLC was firstly reported by a research team. In this study, 223 patients were enrolled to receive the chemotherapy regimen with bevacizumab. Peripheral blood of patients were assessed at baseline and after the first and second treatment cycles for the proportion of T cells, B cells, and monocytes.
Researchers found that after 6 weeks of starting the treatment, the proportion of T cells was significantly increased relative to baseline. Within subsets of T cells, CD4 T cells remained stable, while proliferation of Ki67–positive CD8 T cells significantly increased. More programmed death receptor 1 (PD-1) are expressed by these CD8 T cells when compared with nonproliferating CD8 T cells. Researchers of this study came to a conclusion that the chemotherapy regimen plus bevacizumab resulted in proliferation of more cells expressing coinhibitory checkpoint molecules. However, increase in the number of cells did not affect progression-free survival (PFS) and overall survival.
Another research group will be discussing about the previous use of bevacizumab that was linked with inferior benefits from PD-1 and programmed death ligand 1 (PD-L1) inhibitors in NSCLC. In this study, 133 patients who had been treated with PD-1/PD-L1 inhibitors were identified by the researchers. Among these patients, 14.2% of them had previous bevacizumab treatment for NSCLC. It was found that patients who had exposure to bevacizumab earlier had shorter PFS than those who had no previous exposure. Researchers of this study came to a conclusion that prior bevacizumab use indicated poorer benefits from anti–PD-1/PD-L1 agents.
Finally, a research team will report on its findings that adding bevacizumab to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) prolongs survival in patients with NSCLC with multiple brain metastases. In this study, 164 patients were studied by the researchers.